DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of migraine for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for other countries covered.

DRG Epidemiology’s migraine forecast will answer the following questions:

  • Of all people diagnosed with migraine, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of migraine over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following migraine subpopulations:

  • Diagnosed prevalent chronic cases by acute-drug-treatment status.
  • Diagnosed prevalent chronic cases by prophylactic-drug-treatment status.
  • Diagnosed prevalent episodic cases by acute-drug-treatment status.
  • Diagnosed prevalent episodic cases by prophylactic-drug-treatment status.
  • Total episodic cases by severity status.
  • Total episodic events.
  • Diagnosed prevalent cases of episodic migraine.
  • Diagnosed prevalent cases of chronic migraine.

Note: Coverage may vary by country.

Table of contents

  • Migraine - Epidemiology - Asia-Pacific
    • Introduction
      • Key Findings
        • Prevalence of Migraine per 1,000 Among People Aged 15+ in 2018 and 2028
        • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Migraine over the Next Ten Years
    • Epidemiology Data
    • Methods
      • Total Migraine Prevalence
      • Episodic Migraine Prevalence
      • Chronic Migraine Prevalence
      • Frequency of Episodic Migraine Attacks
      • Diagnosed Prevalent Cases of Migraine
      • Drug-Treated Prevalent Cases of Migraine
      • Total Migraine Incident Cases
      • Lifetime DALYs Gained
      • Total Episodic events of Migraine
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Migraine
        • Studies Excluded from the Analysis of Migraine
      • Risk/Protective Factors
        • Bibliography

    Author(s): Shilpa Thakur; Abey John, M.P.H.

    Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.

    Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.


    Related Reports

    Migraine - Landscape & Forecast - Disease Landscape & Forecast

    The market for prescription migraine therapies comprises an array of

    View Details

    Migraine | Disease Landscape and Forecast | G7 | 2020

    The market for prescription migraine therapies comprises an array of acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the launch of seve...

    View Details

    Migraine - Geographic Focus: China - Migraine - China In-Depth (China)

    Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s n...

    View Details

    Migraine - Current Treatment - Detailed, Expanded Analysis (EU5)

    According to DRG epidemiology, over 30 million people in the EU5 suffer migraines and over 10% of migraineurs suffer chronic migraine. Migraine prophylaxis is a core treatment approach for high-fre...

    View Details